NCT07484022 2026-03-19
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Not yet recruiting
Clinical Trials
10 trialsNCT07475806 2026-03-17
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Astellas Pharma Inc
Phase 2 Not yet recruiting
NCT07460206 2026-03-10
PRELUDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT07346053 2026-01-16
Chrono-EVP
British Columbia Cancer Agency
Phase 3 Not yet recruiting
NCT06400160 2025-11-25
Clinical Trial of TB511 in Advanced Solid Tumors
Twinpig Biolab, Inc.
Phase 1/2 Not yet recruiting
NCT07244393 2025-11-24
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Cellbion Co., Ltd.
Phase 1 Not yet recruiting
NCT07037004 2025-09-23
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07090369 2025-07-29
LumOnate
Peter MacCallum Cancer Centre, Australia
Phase 1 Not yet recruiting
NCT07027124 2025-06-18
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT06146777 2023-11-29
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Not yet recruiting